AU2002222910A1 - Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders - Google Patents

Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Info

Publication number
AU2002222910A1
AU2002222910A1 AU2002222910A AU2291002A AU2002222910A1 AU 2002222910 A1 AU2002222910 A1 AU 2002222910A1 AU 2002222910 A AU2002222910 A AU 2002222910A AU 2291002 A AU2291002 A AU 2291002A AU 2002222910 A1 AU2002222910 A1 AU 2002222910A1
Authority
AU
Australia
Prior art keywords
acute
treatment
neurodegenerative disorders
chronic neurodegenerative
microglial activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002222910A
Inventor
Lav Kumar Parvathenani
Rand M. Posmantur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2002222910A1 publication Critical patent/AU2002222910A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
AU2002222910A 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders Abandoned AU2002222910A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21808500P 2000-07-13 2000-07-13
US60218085 2000-07-13
US26133201P 2001-01-12 2001-01-12
US60261332 2001-01-12
PCT/US2001/021353 WO2002005825A1 (en) 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AU2002222910A1 true AU2002222910A1 (en) 2002-01-30

Family

ID=26912541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002222910A Abandoned AU2002222910A1 (en) 2000-07-13 2001-07-05 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders

Country Status (3)

Country Link
US (4) US6545019B2 (en)
AU (1) AU2002222910A1 (en)
WO (1) WO2002005825A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
EP1450819A4 (en) 2001-11-02 2008-01-23 Univ California Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
WO2004043218A2 (en) * 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
EP1503734A2 (en) * 2002-04-25 2005-02-09 Brainsgate Ltd. Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
CA2488609A1 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
EP1631271A4 (en) * 2003-05-20 2007-12-12 Univ Johns Hopkins Methods and compositions for delivery of catecholic butanes for treatment of tumors
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
CN100440843C (en) * 2004-05-12 2008-12-03 华为技术有限公司 Ring net and method for realizing service
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US20080096967A1 (en) * 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
KR100679306B1 (en) * 2005-03-31 2007-02-06 아미코젠주식회사 Pharmaceutical composition for treating or preventing a neurological brain disease comprising lignan compounds
KR20090006062A (en) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 Methods of treating influenza viral infections
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
WO2008042896A2 (en) * 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
JP2010511632A (en) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド Compositions and methods of treatment comprising 5-lipoxygenase activated protein inhibitors and nitric oxide modulators
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009052454A2 (en) * 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
US8193730B2 (en) 2008-06-12 2012-06-05 3M Innovative Properties Company Dimmer and illumination apparatus with amplitude ordered illumination of multiple strings of multiple color light emitting devices
US20130310421A1 (en) * 2012-05-18 2013-11-21 Temple University - Of The Commonwealth System Of Higher Education Treatment of amyloid beta amyloidosis
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
AU2015214317B2 (en) * 2014-02-04 2020-01-16 Bioscience Pharma Partners, Llc Use of FLAP inhibitors to reduce neuroinflammation mediated injury in the central nervous system
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN114949010A (en) * 2021-12-30 2022-08-30 九江学院 Application of fructus akebiae extract and separation part thereof in product for preventing or treating neuroinflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6111796A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor

Also Published As

Publication number Publication date
US20020022650A1 (en) 2002-02-21
US20030050322A1 (en) 2003-03-13
US6545019B2 (en) 2003-04-08
WO2002005825A1 (en) 2002-01-24
US20030045570A1 (en) 2003-03-06
US20030045566A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AU2002222910A1 (en) Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
AU2001288628A1 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
IL155795A0 (en) Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AU2002334687A1 (en) Ventricular infarct assist device and methods for using it
AU7538398A (en) Emulsion for well and formation treatment
AU7085100A (en) Method for treating otic disorders
HUP0103856A2 (en) Pharmaceutical composition for the treatment of acute disorders
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2001269799A1 (en) Methods for treating various eye disorders
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
AU2002240401A1 (en) Methods and apparatus for treating hemorrhoids and similar ailments
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU7331300A (en) Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
AU2001294151A1 (en) System and method for the control of behavioral disorders
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU6260999A (en) Methods of treating chronic pain
AU5787999A (en) Method for treating neurodegenerative disorders
AU4689099A (en) Fluid treatment apparatus
AU3339399A (en) Fail-safe device
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
AU2002367087A1 (en) Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
AU2002218439A1 (en) Apparatus for treating body ailments
AUPM456894A0 (en) Treatment for gastric disorders